The Global ADME Toxicology Testing Market is expected to grow at a CAGR of 10% during the forecasting period (2022-2029).
Absorption, distribution, metabolism, and excretion (ADME) toxicology testing is used worldwide to test toxic reactions initiated by molecules during the clinical trial. It is primarily used for conducting various toxicity tests, such as genetic, pharmacological, and chemical tests, that aid in drug discovery, starting from the designing of drugs to drug trials. It includes software to control the difficulty, devices to handle liquids, and detectors to identify active compounds and biomolecular interactions.
The rise in healthcare spending and the high rate of drug molecule failure at a late stage are some factors that are expected to propel market growth. Furthermore, the technological advancement in toxicology testing and the continuous increase in demand for ADME toxicology testing in drug discovery support the market's development worldwide.
Rising healthcare expenditure will continue supporting the growth of the market during the forecast period.
The rising healthcare expenditure is augmenting the number of clinical trials across the globe. According to the World Health Organization (WHO), health spending in the rest of the world economy is increasing at a considerable rate annually. In low-and middle-income economies, healthcare spending is growing at an average of around 6% every year, compared to 4% in developed economies. Governments globally are offering an average of about 51% in the company’s health spending. Therefore, with the rise in health spending, there will be an increase in demand for ADME toxicology testing during the forecast period.
Increasing demand for ADME toxicology testing in drug discovery is driving the growth of the global market.
The rising failing of several drug molecules at the final stage of the clinical trial results in the waste of investment funds in drug development. According to Thermo Fisher Scientific, a US-based pharmaceutical company, around 50% of the drug candidates fail due to inefficacy, and 40% fail due to toxicity. Several drugs, such as sorivudine, mibefradil, and phenylpropanolamine hydrochloride, are discontinued in the market due to toxicity and drug-drug interactions. Therefore, ADME toxicology testing is continuously rising and is performed at the early stage of the drug discovery process.
COVID-19 Impact Analysis
The COVID-19 pandemic has supported the growth of the ADME toxicology testing market. It is used to identify new drug candidates for COVID-19 to evaluate the cell model through ADME toxicology testing. Therefore, the demand for ADME toxicology testing is expected to offer growth to the market value in 2020.
The ADME toxicology testing market has been classified into cell culture, high-throughput, molecular imaging, and OMICS technology based on the technology.
The cell Culture segment accounted for the highest market share in the global market.
Rising exploration in cell culture and its application in molecular biological research and development (R&D) activities are expected to drive market growth. With the introduction of genomic and proteomic shaping, rDNA technique, genetic engineering, cell culture technology has become essential tool for researchers from across the globe. The cell culture with cell models' support, such as stem cells and primary cells, allows generating effective and reliable diagnosis. The diagnosis helps gather information about the cells' efficacy and toxicity, micro-organisms, and tissues in the human body before the clinical trials for drug development. Cell culture technology is growing its prevalence in the pharmaceutical industry due to the increasing demand for oral solutions for various infectious diseases worldwide.
Based on the application, the ADME toxicology testing market has been classified into systemic toxicity, hepatotoxicity, renal toxicity, and neurotoxicity.
The systemic toxicity segment dominated the global ADME toxicology testing market in 2019
Systemic toxicity contributes to the significant share in the ADME toxicology testing market globally. The rise in the toxicity study on the body's circulatory system leads to an increase in the preference for systemic toxicology application for drug distribution. It is considered one of the significant factors for the occurrence of toxic reactions, owing to which multiple organs may fail in an individual’s body. Therefore, it contributes a significant share in the ADME toxicology testing market's growth across the globe.
Based on geography, the study analyzes the ADME toxicology testing market globally, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
North America leads the global market throughout the forecast period.
North America dominated the global ADME toxicology testing market and is expected to retain its position during the forecast period. The US contributed a major share in the North American ADME toxicology testing market in 2019. This growth is due to the rising research funding and the technological advancements in toxicology testing. Moreover, the increasing popularity of cell cultures in drug discovery is further supporting the market growth in the region.
The Asia Pacific is estimated to grow at a considerable growth rate in the ADME toxicology testing market during the forecast period. The region's growth is primarily driven by the expansion of foreign market players in the nation's emerging economies, such as China and India. China majorly contributes to the Asia Pacific ADME toxicology testing market's growth, with India projecting a considerable CAGR during the forecast period.
The ADME toxicology testing market is highly competitive. The key ADME toxicology testing players contributing to the global market's growth include Agilent Technologies, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Eurofins Scientific SE, Miltenyi Biotec, Promega Corporation, SGS Group, Thermo Fisher Scientific Inc. The major players are adopting new product launch and expansion strategies for global growth in the ADME toxicology testing market.
Thermo Fisher Scientific, Inc.
Overview: Thermo Fisher Scientific, Inc. is a medical equipment and devices company based in Massachusetts, the US, and was founded in 1960. The company manufactures scientific instruments, chemicals, and consumables. It offers laboratory equipment, analytical instrument, software, services, reagents, consumables, and supplies to biotech and pharmaceutical, clinical diagnostic labs and hospitals, research institutions, universities, and government agencies. Thermo Fisher operates through Analytical Instruments, Life Sciences Solutions, Specialty Diagnostics, and Laboratory Products & Services segment.
Product Portfolio: The company's portfolio comprises Gibco Hepatocytes, Gibco human spheroid-qualified hepatocytes, and ADME/Tox assays for drug discovery and development,
Get your free sample proposal with a single click!